Mutant human APP exacerbates pathology in a mouse model of NPC and its reversal by a β-cyclodextrin

Human Molecular Genetics

Volumn 21, Issue 22, 2012, Pages 4857-4875

  Maulik, Mahua ^a,b   Ghoshal, Bibaswan ^a   Kim, John ^b   Wang, Yanlin ^a,b   Yang, Jing ^b   Westaway, David ^a,b   Kar, Satyabrata ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AMYLOID PRECURSOR PROTEIN; BETA CYCLODEXTRIN; CATHEPSIN D; CYTOCHROME C; NPC1 PROTEIN; PROTEIN; PROTEIN BAX; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; GENE OVEREXPRESSION; LIFESPAN; MEMORY DISORDER; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NIEMANN PICK DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BETA-CYCLODEXTRINS; CATHEPSIN D; CHOLESTEROL; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; NEUROGLIA; NEURONS; NIEMANN-PICK DISEASE, TYPE C; PHOSPHORYLATION; SYNAPSES; TAU PROTEINS;

MUS; MUS MUSCULUS;

EID: 84868234408     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds322     Document Type: Article

References (74)

1. Mukherjee, S. and Maxfield, F.R. (2004) Lipid and cholesterol trafficking in NPC. Biochim. Biophys. Acta, 1685, 28-37.
2. Pacheco, C.D. and Lieberman, A.P. (2008) The pathogenesis of Niemann-Pick type C disease: a role for autophagy? Expert Rev. Mol. Med., 10, e26.
3. Carstea, E.D., Morris, J.A., Coleman, K.G., Loftus, S.K., Zhang, D., Cummings, C., Gu, J., Rosenfeld, M.A., Pavan, W.J., Krizman, D.B. et al. (1997) Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science, 277, 228-231.
4. Walkley, S.U. and Suzuki, K. (2004) Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim. Biophys. Acta, 1685, 48-62.
5. Kodam, A., Maulik, M., Peake, K., Amritraj, A., Vetrivel, K.S., Thinakaran, G., Vance, J.E. and Kar, S. (2010) Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brains. Glia, 58, 1267-1281.
6. Li, H., Repa, J.J., Valasek, M.A., Beltroy, E.P., Turley, S.D., German, D.C. and Dietschy, J.M. (2005) Molecular, anatomical, and biochemical events associated with neurodegeneration in mice with Niemann-Pick type C disease. J. Neuropathol. Exp. Neurol., 64, 323-333.
7. Jin, L.W., Shie, F.S., Maezawa, I., Vincent, I. and Bird, T. (2004) Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am. J. Pathol., 164, 975-985.
8. Mattsson, N., Zetterberg, H., Bianconi, S., Yanjanin, N.M., Fu, R., Mansson, J.E., Porter, F.D. and Blennow, K. (2011) Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology, 76, 366-372.
9. Saito, Y., Suzuki, K., Nanba, E., Yamamoto, T., Ohno, K. and Murayama, S. (2002) Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity. Ann. Neurol., 52, 351-355.
10. Baudry, M., Yao, Y., Simmons, D., Liu, J. and Bi, X. (2003) Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. Exp. Neurol., 184, 887-903.
11. German, D.C., Quintero, E.M., Liang, C.L., Ng, B., Punia, S., Xie, C. and Dietschy, J.M. (2001) Selective neurodegeneration, without neurofibrillary tangles, in a mouse model of Niemann-Pick C disease. J. Comp. Neurol., 433, 415-425.
12. Goate, A. and Hardy, J. (2012) Twenty years of Alzheimer's disease-causing mutations. J. Neurochem., 120(Suppl. 1), 3-8.
13. Selkoe, D.J. (2008) Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. Handb. Clin. Neurol., 89, 245-260.
14. St George-Hyslop, P.H., McLaurin, J. and Fraser, P.E. (2000) Neuropathological, biochemical and genetic alterations in AD. Drug News Perspect., 13, 281-288.
15. Auer, I.A., Schmidt, M.L., Lee, V.M., Curry, B., Suzuki, K., Shin, R.W., Pentchev, P.G., Carstea, E.D. and Trojanowski, J.Q. (1995) Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol. (Berl), 90, 547-551.
16. Ohm, T.G., Treiber-Held, S., Distl, R., Glockner, F., Schonheit, B., Tamanai, M. and Meske, V. (2003) Cholesterol and tau protein-findings in Alzheimer's and Niemann Pick C's disease. Pharmacopsychiatry, 36(Suppl. 2), S120-126.
17. Kim, J., Basak, J.M. and Holtzman, D.M. (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron, 63, 287-303.
18. Poirier, J., Davignon, J., Bouthillier, D., Kogan, S., Bertrand, P. and Gauthier, S. (1993) Apolipoprotein E polymorphism and Alzheimer's disease. Lancet, 342, 697-699.
19. Nixon, R.A. (2004) Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Am. J. Pathol., 164, 757-761.
20. Kagedal, K., Kim, W.S., Appelqvist, H., Chan, S., Cheng, D., Agholme, L., Barnham, K., McCann, H., Halliday, G. and Garner, B. (2010) Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochim. Biophys. Acta, 1801, 831-838.
21. Kivipelto, M., Helkala, E.L., Laakso, M.P., Hanninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannermaa, A., Tuomilehto, J., Nissinen, A. et al. (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med., 137, 149-155.
22. Notkola, I.L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J. and Nissinen, A. (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology, 17, 14-20.
23. Distl, R., Meske, V. and Ohm, T.G. (2001) Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons. Acta Neuropathol. (Berl), 101, 547-554.
24. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., Runz, H., Kuhl, S., Bertsch, T., von Bergmann, K. et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA, 98, 5856-5861.
25. Grimm, M.O., Grimm, H.S., Tomic, I., Beyreuther, K., Hartmann, T. and Bergmann, C. (2008) Independent inhibition of Alzheimer disease betaand gamma-secretase cleavage by lowered cholesterol levels. J. Biol. Chem., 283, 11302-11311.
26. Martin, M., Dotti, C.G. and Ledesma, M.D. (2010) Brain cholesterol in normal and pathological aging. Biochim. Biophys. Acta, 1801, 934-944.
27. Refolo, L.M., Pappolla, M.A., LaFrancois, J., Malester, B., Schmidt, S.D., Thomas-Bryant, T., Tint, G.S., Wang, R., Mercken, M., Petanceska, S.S. et al. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis., 8, 890-899.
28. Adalbert, R., Nogradi, A., Babetto, E., Janeckova, L., Walker, S.A., Kerschensteiner, M., Misgeld, T. and Coleman, M.P. (2009) Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain, 132, 402-416.
29. Chishti, M.A., Yang, D.S., Janus, C., Phinney, A.L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J. et al. (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem., 276, 21562-21570.
30. Francis, B.M., Kim, J., Barakat, M.E., Fraenkl, S., Yucel, Y.H., Peng, S., Michalski, B., Fahnestock, M., McLaurin, J. and Mount, H.T. (2012) Object recognition memory and BDNF expression are reduced in young TgCRND8 mice. Neurobiol. Aging, 33, 555-563.
31. Reddy, P.H. (2011) Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res., 1415, 136-148.
32. Loftus, S.K., Morris, J.A., Carstea, E.D., Gu, J.Z., Cummings, C., Brown, A., Ellison, J., Ohno, K., Rosenfeld, M.A., Tagle, D.A. et al. (1997) Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science, 277, 232-235.
33. Davidson, C.D., Ali, N.F., Micsenyi, M.C., Stephney, G., Renault, S., Dobrenis, K., Ory, D.S., Vanier, M.T. and Walkley, S.U. (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One, 4, e6951.
34. Liu, B., Turley, S.D., Burns, D.K., Miller, A.M., Repa, J.J. and Dietschy, J.M. (2009) Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc12/2 mouse. Proc. Natl Acad. Sci. USA, 106, 2377-2382.
35. Ramirez, C.M., Liu, B., Taylor, A.M., Repa, J.J., Burns, D.K., Weinberg, A.G., Turley, S.D. and Dietschy, J.M. (2010) Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Pediatr. Res., 68, 309-315.
36. Liu, B., Li, H., Repa, J.J., Turley, S.D. and Dietschy, J.M. (2008) Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J. Lipid Res., 49, 663-669.
37. Hao, Y., Pan, D., Zhang, M., Xu, J., Li, L., Wei, J. and Wang, X. (2009) The neuroprotective effects of cyclin-dependent kinase-5 inhibition in mice with Niemann-Pick disease type C. J. Huazhong Univ. Sci. Technolog. Med. Sci., 29, 324-329.
38. Ahmad, I., Lope-Piedrafita, S., Bi, X., Hicks, C., Yao, Y., Yu, C., Chaitkin, E., Howison, C.M., Weberg, L., Trouard, T.P. et al. (2005) Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice. J. Neurosci. Res., 82, 811-821.
39. Ohm, T.G. and Meske, V. (2006) Cholesterol, statins and tau. Acta Neurol. Scand. Suppl., 185, 93-101.
40. Guillozet-Bongaarts, A.L., Glajch, K.E., Libson, E.G., Cahill, M.E., Bigio, E., Berry, R.W. and Binder, L.I. (2007) Phosphorylation and cleavage of tau in non-AD tauopathies. Acta Neuropathol. (Berl), 113, 513-520.
41. Park, S.Y. and Ferreira, A. (2005) The generation of a 17kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J. Neurosci., 25, 5365-5375.
42. Wang, Y., Garg, S., Mandelkow, E.M. and Mandelkow, E. (2010) Proteolytic processing of tau. Biochem. Soc. Trans., 38, 955-961.
43. Bendiske, J. and Bahr, B.A. (2003) Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis-an approach for slowing Alzheimer disease? J. Neuropathol. Exp. Neurol., 62, 451-463.
44. Amritraj, A., Peake, K., Kodam, A., Salio, C., Merighi, A., Vance, J.E. and Kar, S. (2009) Increased activity and altered subcellular distribution of lysosomal enzymes determine neuronal vulnerability in Niemann-Pick type C1-deficient mice. Am. J. Pathol., 175, 2540-2556.
45. Chwieralski, C.E., Welte, T. and Buhling, F. (2006) Cathepsin-regulated apoptosis. Apoptosis, 11, 143-149.
46. Turk, B., Stoka, V., Rozman-Pungercar, J., Cirman, T., Droga-Mazovec, G., Oresic, K. and Turk, V. (2002) Apoptotic pathways: involvement of lysosomal proteases. Biol. Chem., 383, 1035-1044.
47. Martins, I.J., Berger, T., Sharman, M.J., Verdile, G., Fuller, S.J. and Martins, R.N. (2009) Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J. Neurochem., 111, 1275-1308.
48. Kuzyk, A., Kastyak, M., Agrawal, V., Gallant, M., Sivakumar, G., Rak, M., Del Bigio, M.R., Westaway, D., Julian, R. and Gough, K.M. (2010) Association among amyloid plaque, lipid, and creatine in hippocampus of TgCRND8 mouse model for Alzheimer disease. J. Biol. Chem., 285, 31202-31207.
49. Halford, R.W. and Russell, D.W. (2009) Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan. Proc. Natl Acad. Sci. USA, 106, 3502-3506.
50. Burwell, R.D., Saddoris, M.P., Bucci, D.J. and Wiig, K.A. (2004) Corticohippocampal contributions to spatial and contextual learning. J. Neurosci., 24, 3826-3836.
51. Elrick, M.J., Pacheco, C.D., Yu, T., Dadgar, N., Shakkottai, V.G., Ware, C., Paulson, H.L. and Lieberman, A.P. (2010) Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum. Mol. Genet., 19, 837-847.
52. Middleton, F.A. and Strick, P.L. (1998) Cerebellar output: motor and cognitive channels. Trends Cogn. Sci., 2, 348-354.
53. German, D.C., Liang, C.L., Song, T., Yazdani, U., Xie, C. and Dietschy, J.M. (2002) Neurodegeneration in the Niemann-Pick C mouse: glial involvement. Neuroscience, 109, 437-450.
54. Stein, T.D. and Johnson, J.A. (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J. Neurosci., 22, 7380-7388.
55. Chen, G., Li, H.M., Chen, Y.R., Gu, X.S. and Duan, S. (2007) Decreased estradiol release from astrocytes contributes to the neurodegeneration in a mouse model of Niemann-Pick disease type C. Glia, 55, 1509-1518.
56. Lloyd-Evans, E., Morgan, A.J., He, X., Smith, D.A., Elliot-Smith, E., Sillence, D.J., Churchill, G.C., Schuchman, E.H., Galione, A. and Platt, F.M. (2008) Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med., 14, 1247-1255.
57. Zhang, M., Strnatka, D., Donohue, C., Hallows, J.L., Vincent, I. and Erickson, R.P. (2008) Astrocyte-only Npc1 reduces neuronal cholesterol and triples life span of Npc12/2 mice. J. Neurosci. Res., 86, 2848-2856.
58. Ko, D.C., Milenkovic, L., Beier, S.M., Manuel, H., Buchanan, J. and Scott, M.P. (2005) Cell-autonomous death of cerebellar purkinje neurons with autophagy in Niemann-Pick type C disease. PLoS Genet., 1, 81-95.
59. Lopez, M.E., Klein, A.D., Dimbil, U.J. and Scott, M.P. (2011) Anatomically defined neuron-based rescue of neurodegenerative Niemann-Pick type C disorder. J. Neurosci., 31, 4367-4378.
60. Nixon, R.A. and Cataldo, A.M. (2006) Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J. Alzheimers Dis., 9, 277-289.
61. Morris, M., Maeda, S., Vossel, K. and Mucke, L. (2011) The many faces of tau. Neuron, 70, 410-426.
62. Ballatore, C., Lee, V.M. and Trojanowski, J.Q. (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci., 8, 663-672.
63. Dolan, P.J. and Johnson, G.V. (2010) The role of tau kinases in Alzheimer's disease. Curr. Opin. Drug Discov. Devel., 13, 595-603.
64. Bellucci, A., Rosi, M.C., Grossi, C., Fiorentini, A., Luccarini, I. and Casamenti, F. (2007) Abnormal processing of tau in the brain of aged TgCRND8 mice. Neurobiol. Dis., 27, 328-338.
65. Bu, B., Li, J., Davies, P. and Vincent, I. (2002) Deregulation of Cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci., 22, 6515-6525.
66. Sawamura, N., Gong, J.S., Garver, W.S., Heidenreich, R.A., Ninomiya, H., Ohno, K., Yanagisawa, K. and Michikawa, M. (2001) Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J. Biol. Chem., 276, 10314-10319.
67. Pacheco, C.D., Elrick, M.J. and Lieberman, A.P. (2009) Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. Hum. Mol. Genet., 18, 956-965.
68. Zhang, M., Li, J., Chakrabarty, P., Bu, B. and Vincent, I. (2004) Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am. J. Pathol., 165, 843-853.
69. Liu, M.C., Kobeissy, F., Zheng, W., Zhang, Z., Hayes, R.L. and Wang, K.K. (2011) Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions. A.S.N. Neuro., 3, e00051.
70. Rissman, R.A., Poon, W.W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M.P., LaFerla, F.M., Rohn, T.T. and Cotman, C.W. (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest., 114, 121-130.
71. Rosenbaum, A.I. and Maxfield, F.R. (2011) Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J. Neurochem., 116, 789-795.
72. Aqul, A., Liu, B., Ramirez, C.M., Pieper, A.A., Estill, S.J., Burns, D.K., Repa, J.J., Turley, S.D. and Dietschy, J.M. (2011) Unesterified cholesterol accumulation in late endosomes/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment. J. Neurosci., 31, 9404-9413.
73. Vaucher, E., Fluit, P., Chishti, M.A., Westaway, D., Mount, H.T. and Kar, S. (2002) Object recognition memory and cholinergic parameters in mice expressing human presenilin 1 transgenes. Exp. Neurol., 175, 398-406.
74. D'Hooge, R., Hartmann, D., Manil, J., Colin, F., Gieselmann, V. and De Deyn, P.P. (1999) Neuromotor alterations and cerebellar deficits in aged arylsulfatase A-deficient transgenic mice. Neurosci. Lett., 273, 93-96.